Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Journal Information
Full Title: Front Public Health
Abbreviation: Front Public Health
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Public Health
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest."
"This study was supported by the China AntiCancer Association HER2 Target Chinese Research Fund (no. CETSDSSCORP239018) and the Key Project of Science & Technology Development Fund of Tianjin Education Commission for Higher Education, China (no. 2022ZD064)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025